Monte Financial Group LLC Purchases 1,883 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Monte Financial Group LLC raised its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 92.2% in the 3rd quarter, Holdings Channel reports. The firm owned 3,925 shares of the medical instruments supplier’s stock after buying an additional 1,883 shares during the quarter. Monte Financial Group LLC’s holdings in West Pharmaceutical Services were worth $1,178,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Fulcrum Capital LLC raised its position in shares of West Pharmaceutical Services by 2.0% in the third quarter. Fulcrum Capital LLC now owns 8,124 shares of the medical instruments supplier’s stock worth $2,438,000 after buying an additional 162 shares in the last quarter. Elevated Capital Advisors LLC raised its holdings in shares of West Pharmaceutical Services by 8.8% in the 3rd quarter. Elevated Capital Advisors LLC now owns 1,301 shares of the medical instruments supplier’s stock valued at $391,000 after acquiring an additional 105 shares in the last quarter. Global X Japan Co. Ltd. boosted its position in shares of West Pharmaceutical Services by 19.9% during the 3rd quarter. Global X Japan Co. Ltd. now owns 1,303 shares of the medical instruments supplier’s stock valued at $391,000 after acquiring an additional 216 shares during the last quarter. Eastern Bank bought a new stake in shares of West Pharmaceutical Services during the 3rd quarter valued at about $82,000. Finally, Whittier Trust Co. of Nevada Inc. increased its position in shares of West Pharmaceutical Services by 3.7% in the third quarter. Whittier Trust Co. of Nevada Inc. now owns 21,331 shares of the medical instruments supplier’s stock worth $6,402,000 after purchasing an additional 761 shares during the last quarter. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at West Pharmaceutical Services

In other West Pharmaceutical Services news, VP Charles Witherspoon sold 1,029 shares of West Pharmaceutical Services stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $300.00, for a total transaction of $308,700.00. Following the completion of the sale, the vice president now owns 1,478 shares of the company’s stock, valued at $443,400. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.53% of the stock is owned by insiders.

West Pharmaceutical Services Trading Up 0.0 %

Shares of WST opened at $286.44 on Thursday. West Pharmaceutical Services, Inc. has a 1-year low of $265.00 and a 1-year high of $413.70. The company has a market capitalization of $20.78 billion, a P/E ratio of 40.75, a P/E/G ratio of 10.21 and a beta of 1.01. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.34 and a quick ratio of 1.68. The firm’s 50 day simple moving average is $299.72 and its 200 day simple moving average is $323.06.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share for the quarter, missing the consensus estimate of $1.74 by ($0.22). West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The company had revenue of $702.10 million for the quarter, compared to analysts’ expectations of $729.36 million. During the same quarter last year, the business posted $2.11 EPS. The business’s quarterly revenue was down 6.9% compared to the same quarter last year. Sell-side analysts forecast that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current fiscal year.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.